Module 2: Myeloma Bone Disease: Pathogenesis, Diagnosis, and Treatment
This learning activity has been designated for 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Upon completion of this education program the participant should be able to:
- Describe the pathophysiology involved in the development and progression of bone disease in multiple myeloma;
- Identify the imaging studies and bone markers utilized in the evaluation of myeloma bone disease;
- Identify the various modalities utilized in the treatment of myeloma bone disease and discuss the role of bisphosphonates;
- Describe and discuss the indications and guidelines for therapeutic intervention with bisphosphonates in myeloma;
- Discuss novel therapeutic agents being evaluated for myeloma bone disease.
This learning activity is intended for medical oncologists, hematologists,
stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.
Release Date: December 31, 2008
Expiration date: December 31, 2009
(*Please check this box to proceed - required)
Start the Module